Soda M et al. [67] found that the EML-ALK fusion gene was the driver gene of non-small cell lung cancer, and the clinical studies also confirmed that crizotinib, an ALK inhibitor, could treat non-small cell lung cancers which showed a positive expression of ALK [68]. Here, ALK is linked to non-small cell lung carcinoma.